Histone deacetylase inhibitor restores surfactant protein-C expression in alveolar-epithelial type II cells and attenuates bleomycin-induced pulmonary fibrosis in vivo

Experimental Lung Research

Volumn 41, Issue 8, 2015, Pages 422-434

  Ota, Chiharu ^a   Yamada, Mitsuhiro ^a   Fujino, Naoya ^a   Motohashi, Hozumi ^b   Tando, Yukiko ^a   Takei, Yusuke ^a,c   Suzuki, Takaya ^b   Takahashi, Toru ^a,c   Kamata, Satoshi ^a,b   Makiguchi, Tomonori ^a   Yamaya, Mutsuo ^a   Kubo, Hiroshi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Alveolar epithelial type II cells; epithelial to mesenchymal transition; HDAC inhibitor; pulmonary fibrosis; surfactant protein C

Indexed keywords

BLEOMYCIN; HISTONE H4; MESSENGER RNA; SURFACTANT PROTEIN C; TRICHOSTATIN A; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; TRANSFORMING GROWTH FACTOR BETA1;

A549 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CONTROLLED STUDY; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; HISTONE ACETYLATION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; EPITHELIUM CELL; HUMAN; LUNG; LUNG ALVEOLUS; LUNG ALVEOLUS CELL; METABOLISM; PULMONARY FIBROSIS; TUMOR CELL LINE;

ANIMALS; BLEOMYCIN; CELL LINE, TUMOR; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LUNG; MALE; MICE; MICE, INBRED C57BL; PNEUMOCYTES; PULMONARY ALVEOLI; PULMONARY FIBROSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN C; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84941934548     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2015.1060275     Document Type: Article

References (44)

1. Sisson TH, MendezM, Choi K, Subbotina N, Courey A, Cunningham A, et al.: Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181:254-263.
2. Yamada M, Kubo H, Ota C, Takahashi T, Tando Y, Suzuki T, et al.: The increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cells. Respir Res. 2013;14:95.
3. Balli D, Ustiyan V, Zhang Y, Wang IC, Masino AJ, Ren X, et al.: Foxm1 transcription factor is required for lung fibrosis and epithelial-to-mesenchymal transition. EMBO J. 2013;32:231-244.
4. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, et al.: Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA. 2006;103:13180-13185.
5. Kuroki Y, Voelker DR: Pulmonary surfactant proteins. J Biol Chem. 1994;269:25943-25946.
6. Maguire JA, Mulugeta S, Beers MF: Endoplasmic reticulum stress induced by surfactant protein C BRICHOS mutants promotes proinflammatory signaling by epithelial cells. AmJ Respir Cell Mol Biol. 2011;44:404-414.
7. Glasser SW, Senft AP, Maxfield MD, Ruetschilling TL, Baatz JE, Page K, et al.: Genetic replacement of surfactant protein-C reduces respiratory syncytial virus induced lung injury. Respir Res. 2013;14:19.
8. Lawson WE, Polosukhin VV, Stathopoulos GT, Zoia O, Han W, Lane KB, et al.: Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin. Am J Pathol. 2005;167:1267-1277.
9. Martino D, Prescott S: Epigenetics and prenatal influences on asthma and allergic airways disease. Chest. 2011;139:640-647.
10. Huang SK, Fisher AS, Scruggs AM,White ES,Hogaboam CM, Richardson BC, et al.: Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am J Pathol. 2010;177:2245-2255.
11. Coward WR, Watts K, Feghali-Bostwick CA, Knox A, Pang L: Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol. 2009;29:4325-4339.
12. Coward WR,Watts K, Feghali-Bostwick CA, Jenkins G, Pang L: Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis. Mol Cell Biol. 2010;30:2874-2886.
13. Sanders YY, Hagood JS, Liu H, Zhang W, Ambalavanan N, Thannickal VJ: Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice. Eur Respir J. 2014;43:1448-1458.
14. Huber LC, Distler JH, Moritz F, Hemmatazad H, Hauser T, Michel BA, et al.: Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum. 2007;56:2755-2764.
15. Kaimori A, Potter JJ, Choti M, Ding Z, Mezey E, Koteish AA: Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology. 2010;52:1033-1045.
16. Chen X, Xiao W, Chen W, Luo L, Ye S, Liu Y: The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition of lens epithelial cells. Cell Death Dis. 2013;4:e884.
17. Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, et al.: Histone deacetylase-2 is a key regulator of diabetes-and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol. 2009;297:F729-739.
18. Ramos C, Becerril C,Montano M, Garcia-De-Alba C, Ramirez R, Checa M, et al.: FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol. 2010;299:L222-231.
19. McCormack FX, Kuroki Y, Stewart JJ, Mason RJ, Voelker DR: Surfactant protein A amino acids Glu195 and Arg197 are essential for receptor binding, phospholipid aggregation, regulation of secretion, and the facilitated uptake of phospholipid by type II cells. J Biol Chem. 1994;269:29801-29807.
20. Dahl JA, Collas P: A rapid micro chromatin immunoprecipitation assay (microChIP). Nat Protoc. 2008;3:1032-1045.
21. Lee HB, Noh H, Seo JY, YuMR, Ha H: Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy. Kidney Int. 2007;72:S61-66.
22. Guo Y, Yang MC, Weissler JC, Yang YS: PLAGL2 translocation and SP-C promoter activity - a cellular response of lung cells to hypoxia. Biochem Biophys Res Commun. 2007;360: 659-665.
23. He M, Kubo H, Ishizawa K, Hegab AE, Yamamoto Y, Yamamoto H, et al.: The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1427-1436.
24. Hubner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, et al.: Standardized quantification of pulmonary fibrosis in histological samples. BioTechniques. 2008;44:507-511.
25. Matute-Bello G, Frevert CW, Martin TR: Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008;295:L379-399.
26. Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, Kim DY: Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy. 2005;35:89-96.
27. Glauben R, Sonnenberg E, Wetzel M, Mascagni P, Siegmund B: Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo. J Biol Chem. 2014;289:6142-6151.
28. Barbas-Filho JV, Ferreira MA, Sesso A, Kairalla RA, Carvalho CR, Capelozzi VL: Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). J Clin Pathol. 2001;54: 132-138.
29. Minagawa S, Araya J, Numata T, Nojiri S, Hara H, Yumino Y, et al.: Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-beta-induced senescence of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2011;300:L391-401.
30. Araya J, Kojima J, Takasaka N, Ito S, Fujii S, Hara H, et al.: Insufficient autophagy in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2013;304:L56-69.
31. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, et al.: Future directions in idiopathic pulmonary fibrosis research: an NHLBI workshop report. Am J Respir Crit Care Med. 2014;189:214-222.
32. Xu X, Dai H, Wang C: Epithelium dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: current status and future directions. Clin Respir J. 2014. DOI: 10.1111/crj.12190.
33. Glant TT, Mikecz K, Rauch TA: Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med. 2014;12:35.
34. Wada TT, Araki Y, Sato K, Aizaki Y, Yokota K, Kim YT, et al.: Aberrant histone acetylation contributes to elevated interleukin-6 production in rheumatoid arthritis synovial fibroblasts. Biochem Biophys Res Commun. 2014;444:682-686.
35. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, et al.: Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol. 2006;176:5015-5022.
36. Hu N, Qiu X, Luo Y, Yuan J, Li Y, LeiW, et al.: Abnormal histonemodification patterns in lupus CD4+ T cells. J Rheumatol. 2008;35:804-810.
37. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, et al.: The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA. 2002;99:2995-3000.
38. Vojinovic J,DamjanovN,D'Urzo C, Furlan A, SusicG, Pasic S, et al.: Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:1452-1458.
39. Makarona K, Caputo VS, Costa JR, Liu B, O'Connor D, Iskander D, et al.: Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-deficient cells. Blood. 2014;124:134-141.
40. Hutt DM, HermanD, Rodrigues AP,Noel S, Pilewski JM,Matteson J, et al.: Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol. 2010;6:25-33.
41. Hasan MR, Kim JH, Kim YJ, Kwon KJ, Shin CY, Kim HY, et al.: Effect ofHDACinhibitors on neuroprotection and neurite outgrowth in primary rat cortical neurons following ischemic insult. Neurochem Res. 2013;38:1921-1934.
42. Yoshikawa M, Hishikawa K, Idei M, Fujita T: Trichostatin a prevents TGF-beta1-induced apoptosis by inhibiting ERK activation in human renal tubular epithelial cells. Eur J Pharmacol. 2010;642:28-36.
43. Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J, et al.: Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci USA. 2011;108:E1475-1483.
44. Suliman BA, Xu D, Williams BR: HDACi: molecular mechanisms and therapeutic implications in the innate immune system. Immunol Cell Biol. 2012;90:23-32.